Skip to main content
MAXCYTE, INC. logo

MAXCYTE, INC. — Investor Relations & Filings

Ticker · MXCT ISIN · US57777K1060 LEI · 54930053YHXULRFCU991 US Professional, scientific and technical activities
Open in API
Filings indexed 767 across all filing types
Latest filing 2023-07-31 Director's Dealing
Country US United States of America
Listing US MXCT

About MAXCYTE, INC.

https://www.maxcyte.com/

MaxCyte, Inc. is a cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of cell-based therapeutics. Its core offering is the ExPERT™ platform, which utilizes proprietary Flow Electroporation® technology for efficient, scalable, and non-viral transfection of complex cells. This technology supports a wide range of applications, including cell therapy, gene editing, antibody and protein production, and vaccine development. Additionally, MaxCyte offers SeQure™ genotoxicity assessment services to evaluate the safety of gene-edited products by detecting on- and off-target effects. The company employs a partnership-driven licensing model to support clients from early-stage research through to clinical and commercial manufacturing.

Recent filings

Filing Released Lang Actions
Exercise of options and PDMR dealing
Director's Dealing Classification · 1% confidence The document is an official notification of a transaction in company shares by a Person Discharging Managerial Responsibilities (PDMR), specifically a Non-Executive Director. It includes the required regulatory disclosure tables detailing the nature of the transaction (exercise of options and subsequent sale), price, volume, and date. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2023-07-31 English
FORM 4 SUBMISSION
Director's Dealing
2023-07-28 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is a standard regulatory filing used in the UK to disclose when a shareholder's interest in a company crosses specific voting rights thresholds. This document explicitly details BlackRock, Inc.'s shareholding in MaxCyte, Inc. and follows the regulatory format for major shareholding notifications. Therefore, it falls under the 'Major Shareholding Notification' category.
2023-07-26 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is the standard regulatory filing used in the UK to disclose when a shareholder's interest in a company crosses specific voting rights thresholds. It identifies BlackRock, Inc. as the entity subject to the notification obligation regarding its holdings in MaxCyte, Inc. This falls under the 'Major Shareholding Notification' category.
2023-07-24 English
TR-1: Notification of major holdings
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Notification of major holdings' form, which is the standard regulatory filing used in the UK to report changes in significant share ownership (crossing thresholds). This falls directly under the definition of a 'Major Shareholding Notification'.
2023-07-24 English
Notice of Second Quarter 2023 Financial Results
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5,000 characters) from MaxCyte, Inc. regarding the upcoming release of their second quarter 2023 financial results and the scheduling of an earnings conference call. It does not contain the actual financial results, but rather serves as a notification of when those results will be published. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2023-07-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.